In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method

Biochem Biophys Res Commun. 1997 Feb 24;231(3):540-5. doi: 10.1006/bbrc.1996.5762.

Abstract

Although antisense strategy has been at the center of interest in gene therapy, little is known about application of this strategy to cardiac diseases because of the lack of a suitable delivery method into the heart. Therefore, we compared the transfection efficiency of antisense oligodeoxynucleotides (ODN) using HVJ-liposome method and direct transfer in in vivo transfer into heart. To investigate the cellular fate and localization of ODN, transfer of "naked" FITC-labeled antisense ODN or ODN enwrapped in HVJ-liposome complex were examined. Following in vivo transfer using direct injection as well as in vitro transfer, fluorescence rapidly disappeared within 1 day, whereas transfer by HVJ-liposome method resulted in sustained fluorescence localized in the nucleus for at least 1 week. Measurement of fluorescence also demonstrated a significantly higher level in myocardium transfected by HVJ-liposome method than direct transfer. The present study demonstrated that HVJ-liposome method is more efficacious for ODN delivery by prolongation of half-life of ODN, suggesting its usefulness for gene therapy in cardiac diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Genetic Therapy / methods*
  • Liposomes
  • Myocardium* / enzymology
  • Oligonucleotides, Antisense / administration & dosage*
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Respirovirus

Substances

  • Liposomes
  • Oligonucleotides, Antisense
  • Peptidyl-Dipeptidase A